McLeod Health

Omalizumab (Xolair) Treatment Plan

Patient Name:				_ DOB:		
Height (cm):		Weight (kg):		Allergies:		
Patient Primar	y Phone Number:					
Diagnosis (sele	ect one):					
□ J45.50 Severe persistent asthma, unspecified						
□ J45.51 Severe persistent asthma with (acute) exacerbation						
□ J45.52 Severe persistent asthma with status asthmaticus						
Other: ICD 10 Code: Diagnosis Description:						
Drug Orders:						
Omalizumab	(Xolair) (J2357) via sub	cutaneous inje	ction			
• Dose: 🗆 75 m	ng 🛛 150 mg	🗆 225 mg	🗆 300 mg	□ 375 mg		
• Frequency:	Every 2 weeks					
	Every 4 weeks					
	□ Other:					
• Order Durati	on: Six months unless o	otherwise speci	fied (Other:)	
Standing Orde	<u>rs:</u>					
• Monitor pati	ent for 2 hours followin	ng first 3 injectio	ons and 30 minut	es after subsequent injec	tions	
	ction Protocol (CPOE-1 ion will be stopped and	-		ersensitivity reaction occu	urs, including anaphylaxis.	

Physician Signature:	Date:
Physician Name:	Phone:

Pre-Screening Requirements:

• Provide pre-treatment serum IgE level to confirm dosing

Previous Therapies:

- For new patient referrals, please send history and physical and most recent physician note with completed plan
- If patient has previously received omalizumab at another facility, please provide last date received: ______
- If patient has previously received another biologic therapy, please provide the name: ______

and the last date received: _____

Insurance Information:

Insurance Plan Name:						
Insurance Identification Number:						
Insurance Customer Service Contact Number:						
Preferred Treatment Location						
McLeod Regional Medical Center (Florence)	McLeod Health Loris	McLeod Health Cheraw				
McLeod Health Seacoast (Little River)	McLeod Health Dillon	McLeod Health Clarendon	(Manning)			

Fax completed Treatment Plan to the McLeod Medication Access Team at 843-777-9798. For any questions, please contact our team at medicationaccessteam@mcleodhealth.org.